Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOMAR vs ERGOLOID MESYLATES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Abortive treatment of acute migraine headaches with or without aura,Cluster headache
Treatment of age-related cognitive decline,Dementia (unlabeled use)
Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Terminal elimination half-life is approximately 2-3 hours for ergotamine, but clinical effects may persist longer due to active metabolites (e.g., ergotamine's half-life is 2.4 hours; metabolites have half-lives up to 10 hours).
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Primarily hepatic via CYP3A4; minor contributions from CYP2D6. Undergoes extensive first-pass metabolism.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Primarily hepatic metabolism with extensive biliary excretion; less than 5% excreted unchanged in urine. Fecal elimination accounts for approximately 30-40% of the dose as metabolites.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
90-95% bound to plasma proteins, primarily albumin.
Approximately 90% bound to albumin.
Approximately 0.4 L/kg (16-18 L in adults), indicating moderate tissue distribution.
1.5-2 L/kg, indicating extensive tissue distribution.
Sublingual: ~40-50%; Oral: <10% due to extensive first-pass metabolism; Rectal: ~25-30%.
Oral: less than 10% due to extensive first-pass metabolism.
GFR > 30 m L/min: No adjustment. GFR 10-30 m L/min: Caution; reduce dose by 50%. GFR < 10 m L/min: Contraindicated.
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
Child-Pugh A: Caution; reduce dose by 50%. Child-Pugh B: Contraindicated. Child-Pugh C: Contraindicated.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Not recommended for children under 12 years. Pediatric use not established; avoid use.
Not established; safety and efficacy not determined in pediatric patients.
Elderly patients are more sensitive to vasoconstriction; use lower initial dose (e.g., 1 mg) and monitor for adverse effects.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Serious and/or life-threatening peripheral ischemia and vasospasm have been associated with the concomitant use of ergotamine with potent CYP3A4 inhibitors including protease inhibitors, macrolide antibiotics, and azole antifungals.
No FDA black box warning.
Risk of ischemic events (peripheral, cardiac, cerebral), fibrosis (retroperitoneal, pulmonary, cardiac), elderly patients (more sensitive to adverse effects), ergotism, drug interactions with CYP3A4 inhibitors, and prolonged use leading to medication-overuse headache.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Hypersensitivity to ergot alkaloids, peripheral vascular disease, coronary artery disease, uncontrolled hypertension, sepsis, hepatic or renal impairment, pregnancy, breastfeeding, concomitant use with potent CYP3A4 inhibitors, hemiplegic or basilar migraine.
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, increasing ergotamine levels and risk of toxicity. No other significant food interactions.
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trimester: Increased risk of spontaneous abortion and major malformations (e.g., limb defects, CNS abnormalities) based on case reports. Second and third trimesters: Uterine hypertonicity and decreased placental perfusion leading to fetal distress, preterm labor, and low birth weight. Use only if benefit outweighs risk and no alternative; avoid in all trimesters.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Ergotamine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.5-0.9. Potential for ergotism symptoms in infants (vomiting, diarrhea, seizures). It may also reduce milk production due to prolactin inhibition. Contraindicated during breastfeeding per manufacturer guidelines. If exposure occurs, monitor infant for symptoms and consider abrupt cessation.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Pregnancy may alter ergotamine pharmacokinetics (increased plasma volume, renal clearance, hepatic metabolism), but no established dose adjustment guidelines. Standard doses may be ineffective or toxic due to variable absorption. Avoid use if possible; if necessary, lowest effective dose for shortest duration, with close monitoring for toxicity.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
Ergomar (ergotamine tartrate sublingual tablets) is a first-line abortive therapy for acute migraine attacks, but its use is limited by vasoconstrictive risks. Avoid in patients with coronary artery disease, hypertension, peripheral vascular disease, or pregnancy. Administer at the first sign of migraine; sublingual route offers rapid absorption. Concomitant use with potent CYP3A4 inhibitors (e.g., macrolides, protease inhibitors) is contraindicated due to risk of ergotism. Limit total dose to 6 mg per attack and 10 mg per week.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
Take one sublingual tablet at the first sign of migraine, placing it under the tongue to dissolve, and do not swallow.,Do not exceed 3 tablets per attack or 5 tablets per week; overuse can lead to serious side effects.,Seek immediate medical attention if you experience symptoms of ergotism like severe coldness, numbness, or pain in hands/feet, muscle cramps, chest pain, or rapid heartbeat.,Avoid grapefruit and grapefruit juice during treatment as it may increase the risk of side effects.,Inform your doctor if you are pregnant, breastfeeding, or have any history of heart disease, high blood pressure, or peripheral artery disease.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOMAR vs ERGOLOID MESYLATES, answered by our medical review team.
ERGOMAR is a Ergot Alkaloid Antimigraine that works by Ergotamine acts as a partial agonist at serotonin 5-HT1B and 5-HT1D receptors, causing vasoconstriction of cranial blood vessels. It also inhibits norepinephrine reuptake and has alpha-adrenergic blocking activity.. ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOMAR and ERGOLOID MESYLATES depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOMAR is: Ergotamine tartrate 1-2 mg sublingually or orally at onset of migraine, then 1-2 mg every 30 minutes as needed, maximum 6 mg per attack and 10 mg per week.. The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOMAR and ERGOLOID MESYLATES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOMAR is classified as Category C. Ergotamine (ERGOMAR) is contraindicated in pregnancy due to its oxytocic properties and potential for uterine hyperstimulation, fetal hypoxia, and congenital anomalies. First trime. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.